← Every applicant
Yichang Humanwell FDA Approvals
15 new drug approvals and 0 device clearances on file. This applicant is not matched to a listed company.
Newest first
A new drug approval is an original application; a 510(k) is a device shown equivalent to one already sold.
| Product |
|---|
| DILTIAZEM HYDROCHLORIDENew drugSep 25, 2026TABLET, ORAL |
| BUPROPION HYDROCHLORIDENew drugMay 4, 2026TABLET, EXTENDED RELEASE, ORAL |
| DESVENLAFAXINE SUCCINATENew drugMar 10, 2026TABLET, EXTENDED RELEASE, ORAL |
| MICAFUNGIN SODIUMNew drugFeb 24, 2026INJECTABLE, INTRAVENOUS |
| RIVASTIGMINENew drugSep 23, 2025FILM, EXTENDED RELEASE, TRANSDERMAL |
| CARBAMAZEPINENew drugJan 16, 2025TABLET, EXTENDED RELEASE, ORAL |
| FENOFIBRATENew drugApr 24, 2024TABLET, ORAL |
| BUPROPION HYDROCHLORIDENew drugJan 9, 2023TABLET, EXTENDED RELEASE, ORAL |
| FLECAINIDE ACETATENew drugSep 8, 2022TABLET, ORAL |
| IBUPROFENNew drugMar 30, 2022TABLET, ORAL |
| VENLAFAXINE HYDROCHLORIDENew drugAug 6, 2021CAPSULE, EXTENDED RELEASE, ORAL |
| MEMANTINE HYDROCHLORIDENew drugApr 2, 2021CAPSULE, EXTENDED RELEASE, ORAL |
| DIVALPROEX SODIUMNew drugMar 15, 2021TABLET, EXTENDED RELEASE, ORAL |
| METOPROLOL SUCCINATENew drugFeb 12, 2021TABLET, EXTENDED RELEASE, ORAL |
| MYCOPHENOLATE SODIUMNew drugFeb 10, 2021TABLET, DELAYED RELEASE, ORAL |